drugset / Trial / NCT00192621
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
Phase 4
Completed
50 enrolled
Kirby Institute
Garvan Institute of Medical Research · collabNational Heart, Lung, and Blood Institute (NHLBI) · collabPrince of Wales Hospital, Sydney · collabSt Vincent's Hospital, Sydney · collab
NaSingle-groupOpen-labelBasic science
Summary
This is a randomised study of the effect of treatment with Combivir (zidovudine \[AZT\] and lamivudine \[3TC\]) and Kaletra (lopinavir \[LPVr\]), alone and in combination, on the development of abnormalities in lipid and glucose metabolism in HIV negative healthy subjects.
Timeline
- Start
- 2004-11
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lamivudine | Other / unclassified | — | — |
| Subject | Lopinavir | Other / unclassified | — | — |
| Subject | Zidovudine | Small molecule | — | — |